On Monday, KeyBanc Capital Markets maintained its Overweight rating on Revvity Inc (NYSE: RVTY) with a steady price target of $132.00. Revvity's third-quarter 2024 performance surpassed consensus expectations and prompted an upward revision of its earnings per share (EPS) forecast for the year. Concurrently, the company tempered its revenue outlook, citing challenges that are impacting the industry.
Revvity's updated guidance reflects a mixed picture, with lower revenue projections due to a decline in China's market, described as low single-digit (LSD) downturn, and reduced capital equipment expenditure. Despite these headwinds, the company noted a gradual uptick in activity from pharmaceutical and biotechnology customers. This observation aligns with KeyBanc's assessment that the life science tools sector is on a path to recovery.
The positive developments at Revvity echo recent favorable outcomes for industry counterparts, with companies like Waters Corporation (NYSE: NYSE:WAT) and Bio-Techne (NASDAQ:TECH) Corporation (NASDAQ: TECH) also reporting encouraging results. This trend suggests a broader resurgence in the life science tools market, which may be bolstered by increased funding for pharmaceutical and biotechnology ventures in the near future.
KeyBanc has adjusted its financial model for Revvity to account for the third-quarter results and the company's revised forecasts. The firm anticipates that order inflows—and subsequently revenues—will benefit from the gradual improvement in funding for the company's pharma and biotech clients, which could drive Revvity's performance in the upcoming quarters.
In other recent news, Revvity Inc. outperformed Q3 expectations and subsequently elevated its full-year earnings per share (EPS) forecast. The company's Q3 earnings exceeded analyst estimates, primarily driven by its thriving Diagnostics segment, and revenue for the quarter was $684 million, a 2% year-on-year increase. The Diagnostics segment witnessed a 6% YoY revenue growth, whereas the Life Sciences segment experienced a 2% YoY revenue decline.
Evercore ISI raised Revvity's price target to $134, maintaining an outperform rating. This adjustment came after Revvity announced a 2% organic growth, slightly above standard expectations, and an approximate 8% increase in EPS YoY. Despite a reduction in the FY24 organic growth outlook, Revvity's shares saw a 3% increase.
Revvity also announced a 150 million share repurchase and a new 1 billion buyback plan, signaling management's confidence in market recovery. The company has revised its full-year 2024 adjusted EPS guidance to a range of $4.83 to $4.87, surpassing the analyst consensus of $4.75. The company has also updated its full-year revenue guidance to $2.75-$2.77 billion.
InvestingPro Insights
Revvity Inc's financial health and market position appear to align with KeyBanc's Overweight rating. According to InvestingPro data, the company's net income is expected to grow this year, which supports the positive outlook despite the tempered revenue guidance. This growth expectation is particularly noteworthy given the industry challenges mentioned in the article.
An InvestingPro Tip highlights that Revvity has maintained dividend payments for 54 consecutive years, demonstrating a strong commitment to shareholder returns even in fluctuating market conditions. This long-standing dividend history could be attractive to investors looking for stability in the life science tools sector.
Another relevant InvestingPro Tip indicates that Revvity operates with a moderate level of debt. This financial prudence could provide the company with flexibility to navigate the current market challenges and potentially capitalize on the gradual uptick in pharmaceutical and biotechnology customer activity mentioned in the article.
For investors seeking a more comprehensive analysis, InvestingPro offers 8 additional tips that could provide further insights into Revvity's financial position and market prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.